These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32819210)

  • 21. Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda.
    Kagaayi J; Batte J; Nakawooya H; Kigozi B; Nakigozi G; Strömdahl S; Ekström AM; Chang LW; Gray R; Reynolds SJ; Komaketch P; Alamo S; Serwadda D
    J Int AIDS Soc; 2020 Aug; 23(8):e25588. PubMed ID: 32785976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retention in an mHealth App Aiming to Promote the Use of HIV Pre-Exposure Prophylaxis Among Female Sex Workers in Dar es Salaam, Tanzania: Prospective Cohort Study.
    Mbotwa CH; Kazaura MR; Moen K; Leshabari MT; Metta E; Mmbaga EJ
    JMIR Mhealth Uhealth; 2023 Oct; 11():e46853. PubMed ID: 37855221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
    Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
    J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis.
    Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P
    J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV risk and pre-exposure prophylaxis interest among female bar workers in Dar es Salaam: cross-sectional survey.
    Harling G; Muya A; Ortblad KF; Mashasi I; Dambach P; Ulenga N; Barnhart D; Mboggo E; Oldenburg CE; Bärnighausen T; Spiegelman D
    BMJ Open; 2019 Mar; 9(3):e023272. PubMed ID: 30898799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city.
    Peitzmeier SM; Tomko C; Wingo E; Sawyer A; Sherman SG; Glass N; Beyrer C; Decker MR
    AIDS Care; 2017 Nov; 29(11):1453-1457. PubMed ID: 28271718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex with Men in a Community-Based Sexual Health Clinic.
    Hojilla JC; Vlahov D; Crouch PC; Dawson-Rose C; Freeborn K; Carrico A
    AIDS Behav; 2018 Apr; 22(4):1096-1099. PubMed ID: 29243109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing PrEP and early HIV treatment interventions for implementation among female sex workers in South Africa: developing and learning from a formative research process.
    Eakle R; Mutanha N; Mbogua J; Sibanyoni M; Bourne A; Gomez G; Venter F; Rees H
    BMJ Open; 2018 Jun; 8(6):e019292. PubMed ID: 29903784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in eThekwini, South Africa, 2016-2020.
    Rao A; Mhlophe H; Comins C; Young K; Mcingana M; Lesko C; Mulumba N; Baral S; Hausler H; Schwartz S
    PLoS One; 2022; 17(3):e0265434. PubMed ID: 35290421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Pre-Exposure Prophylaxis Adherence among Female Sex Workers.
    Ghayda RA; Hong SH; Yang JW; Jeong GH; Lee KH; Kronbichler A; Solmi M; Stubbs B; Koyanagi A; Jacob L; Oh H; Kim JY; Shin JI; Smith L
    Yonsei Med J; 2020 May; 61(5):349-358. PubMed ID: 32390358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in Côte d'Ivoire: the ANRS 12381 PRINCESSE project.
    Becquet V; Nouaman M; Plazy M; Agoua A; Zébago C; Dao H; Montoyo A; Jary A; Coffie PA; Eholié S; Larmarange J;
    BMC Public Health; 2021 Dec; 21(1):2214. PubMed ID: 34863122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of HIV Preexposure Prophylaxis Adherence Among Female Sex Workers in a Demonstration Study in Cotonou, Benin: A Study of Behavioral and Demographic Factors.
    Mboup A; Diabaté S; Béhanzin L; Guédou FA; Zannou DM; Kêkê RK; Bachabi M; Gangbo F; Marzinke MA; Hendrix C; Gagnon MP; Alary M
    Sex Transm Dis; 2021 Aug; 48(8):565-571. PubMed ID: 33448731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost of pre-exposure prophylaxis delivery in family planning clinics to prevent HIV acquisition among adolescent girls and young women in Kisumu, Kenya.
    Wanga V; Peebles K; Obiero A; Mogaka F; Omollo V; Odoyo JB; Morton JF; Bukusi EA; Celum C; Baeten JM; Barnabas RV
    PLoS One; 2021; 16(4):e0249625. PubMed ID: 33857195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand.
    Azariah S; Saxton P; Franklin R; Forster R; Werder S; Jenkins R
    BMJ Open; 2019 Jun; 9(6):e026363. PubMed ID: 31248921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
    AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential Impact of Interventions to Enhance Retention in Care During Real-World HIV Pre-Exposure Prophylaxis Implementation.
    Chan PA; Goedel WC; Nunn AS; Sowemimo-Coker G; Galárraga O; Prosperi M; Patel R; Mena L; Montgomery MC; Marshall BDL
    AIDS Patient Care STDS; 2019 Oct; 33(10):434-439. PubMed ID: 31584857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV.
    Gombe MM; Cakouros BE; Ncube G; Zwangobani N; Mareke P; Mkwamba A; Prescott MR; Bhatasara T; Murwira M; Mangwiro AZ; Prust ML
    PLoS One; 2020; 15(1):e0227632. PubMed ID: 31931514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.